VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 127 filers reported holding VAXCYTE INC in Q3 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,732,168 | +16.0% | 92,824 | +13.6% | 0.00% | +50.0% |
| Q2 2023 | $4,079,549 | +275.8% | 81,689 | +182.1% | 0.00% | +100.0% |
| Q1 2023 | $1,085,421 | -20.6% | 28,960 | +1.6% | 0.00% | 0.0% |
| Q4 2022 | $1,366,431 | +174.5% | 28,497 | +37.4% | 0.00% | – |
| Q3 2022 | $497,832 | +10.2% | 20,743 | -0.1% | 0.00% | – |
| Q2 2022 | $451,651 | +6.8% | 20,756 | +18.5% | 0.00% | – |
| Q1 2022 | $422,842 | -17.3% | 17,509 | -18.5% | 0.00% | – |
| Q4 2021 | $511,000 | -5.7% | 21,480 | +0.5% | 0.00% | – |
| Q3 2021 | $542,000 | +5.2% | 21,379 | -6.6% | 0.00% | – |
| Q2 2021 | $515,000 | +56.5% | 22,888 | +37.6% | 0.00% | – |
| Q1 2021 | $329,000 | +10.0% | 16,639 | +47.8% | 0.00% | – |
| Q4 2020 | $299,000 | -39.2% | 11,260 | +13.0% | 0.00% | -100.0% |
| Q3 2020 | $492,000 | – | 9,963 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |